Drugs in Dev. Neurology
Phase III
Taiwan 
Lead Product(s) : Clobetasol Propionate
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Cristalia Produtos Quimicos Farma. Ltda
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Formosa Pharmaceuticals Licenses APP13007 for Inflammation and Pain Post-Ocular Surgery
Details : Under the agreement, Cristália gets exclusive Brazilian rights for commercializing APP13007 (clobetasol propionate ophthalmic nanosuspension) for inflammation and pain following ocular surgery.
Product Name : APP13007
Product Type : Steroid
Upfront Cash : Undisclosed
January 26, 2024
Lead Product(s) : Clobetasol Propionate
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Cristalia Produtos Quimicos Farma. Ltda
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Clobetasol Propionate
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Eyenovia
Deal Size : Undisclosed
Deal Type : Acquisition
Details : Through the acquisition, Eyenovia has gained the exclusive U.S. rights to distribute and sell APP13007 (clobetasol propionate ophthalmic nanosuspension), a potent steroid for reducing the inflammation and pain associated with ocular surgery, which is und...
Product Name : APP13007
Product Type : Steroid
Upfront Cash : Undisclosed
August 16, 2023
Lead Product(s) : Clobetasol Propionate
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Eyenovia
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : Clobetasol Propionate
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : AimMax Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : APP13007 (clobetasol propionate ophthalmic nanosuspension) is expected to provide ophthalmologists and ocular surgery patients with a compelling, rapid and sustained, and more convenient postoperative anti-inflammatory and pain relief solution.
Product Name : APP13007
Product Type : Steroid
Upfront Cash : Inapplicable
May 05, 2023
Lead Product(s) : Clobetasol Propionate
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : AimMax Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Clobetasol Propionate
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : AimMax Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : There were 26.5% of subjects who showed sustained anterior chamber cell (ACC) count = 0 (inflammation free) from post-operative day 8 (POD8) through POD15 in the APP13007 (clobetasol propionate) arm as compared to 5.1% in the placebo arm (p<0.001).
Product Name : APP13007
Product Type : Steroid
Upfront Cash : Inapplicable
December 05, 2022
Lead Product(s) : Clobetasol Propionate
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : AimMax Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Clobetasol Propionate
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : AimMax Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Data showed statisticallly-significant and clinically-meaningful improvement of inflammation and pain with twice-daily APP13007 compared to matching placebo, a regimen that is being evaluated in ongoing Phase 3 studies.
Product Name : APP13007
Product Type : Steroid
Upfront Cash : Inapplicable
April 28, 2022
Lead Product(s) : Clobetasol Propionate
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : AimMax Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
